Neximmune, Inc. Stock Price, News & Analysis

NexImmune, Inc. (Nasdaq: NEXI), in collaboration with JDRF and Yale, has received a $600,000 grant to research the use of its AIM nanoparticles with anti-CD3 mAb for type 1 diabetes (T1D). The two-year study aims to explore the potential for this combination therapy to modulate T cells linked to T1D. Dr. Jack Ragheb of NexImmune highlighted the technology’s capability to target autoreactive T cells. This initiative supports JDRF’s mission to accelerate advancements in T1D treatment.

NexImmune, a clinical-stage biotechnology firm (Nasdaq: NEXI), has appointed Dr. Leena Gandhi, Director at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director. Dr. Gandhi, an expert in immuno-oncology, expressed enthusiasm for advancing NexImmune's novel immunotherapy technology, which aims to enhance targeted immune responses. The company is focused on developing its AIM™ nanoparticle technology for treating various cancers, with two lead programs currently in Phase 1/2 clinical trials for relapsed AML and multiple myeloma.

NexImmune (Nasdaq: NEXI), a clinical-stage biotechnology firm, announced a preclinical research partnership with Columbia University’s Herbert Irving Comprehensive Cancer Center. The collaboration aims to explore the use of NexImmune’s adoptive cell therapy, AIM ACT, in treating HPV-related cancers, particularly head and neck squamous cell carcinoma. This partnership is poised to address significant unmet needs in HPV-associated cancers, leveraging Columbia's innovative patient-derived organoid models to assess therapeutic potential.

NexImmune, Inc. (Nasdaq: NEXI) announced the promotion of Mathias Oelke, Ph.D., to Chief Scientific Officer. A scientific co-founder, Dr. Oelke has over 20 years of experience in cancer immunotherapy and has been instrumental in NexImmune’s progress. He will lead ongoing development of the company's proprietary Artificial Immune Modulation (AIM™) technology, which aims to enhance T cell responses against cancer. NexImmune’s lead clinical programs, NEXI-001 and NEXI-002, are currently in Phase 1/2 trials for treating relapsed AML and multiple myeloma, respectively.

NexImmune and Zephyr AI have announced a strategic partnership to advance T-cell-mediated therapies in oncology. This collaboration will leverage Zephyr's AI technology for target discovery and NexImmune’s AIM platform for validation. The focus is on identifying optimal antigens for potential new cancer therapeutics, aiming to enhance treatment for patients with solid and hematological cancers. The partnership is expected to accelerate drug discovery, reduce costs, and improve patient outcomes through innovative cancer treatment approaches.

NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced a research collaboration with The Laura and Isaac Perlmutter Cancer Center to evaluate its artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific T cells from melanoma patients. The collaboration will be guided by Dr. Jeffrey S. Weber, Deputy Director of the center. The AIM technology platform aims to validate the targeting of neoantigens across various cancers, enhancing the development of innovative therapies for cancer patients.

NexImmune, a clinical-stage biotechnology company, will have its CEO, Kristi Jones, present at the Barclays 2022 Global Healthcare Conference on March 17, 2022, at 8:30 a.m. ET. The presentation will provide insights into the company's innovative immunotherapy approach that utilizes proprietary AIM nanoparticle technology to target T cells for a robust immune response. NexImmune's lead programs, NEXI-001 and NEXI-002, are in clinical trials for treating relapsed AML post-stem cell transplantation and refractory multiple myeloma. A replay will be available for 30 days post-conference.

NexImmune, a clinical-stage biotechnology company, reported significant advancements in 2021, driven by a successful $126.5M IPO. Key highlights include robust immune responses in Phase 1/2 trials of NEXI-001 and NEXI-002, with no severe adverse events, and plans to submit an IND for NEXI-003 in 1H22. Financially, cash reserves increased to $81.8M, enabling operations into Q2 2023, despite a net loss of $50.9M for the year. The company aims to release further clinical updates in the latter half of 2022, showcasing its commitment to advancing immunotherapy treatments.

NexImmune, a clinical-stage biotechnology company, announced the appointment of Kristi Jones as its new Chief Executive Officer following the resignation of Scott Carmer. Jones, who has been with the company since 2017 and previously served as Chief Business Officer and Chief Operating Officer, brings over 25 years of experience in the biotechnology and pharmaceutical sectors. The company is advancing its immunotherapy platform using proprietary AIM™ nanoparticle technology, with lead programs NEXI-001 and NEXI-002 currently in Phase 1/2 trials.